Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, POLYSOMNOGRAPHY STUDY TO ASSESS THE EFFICACY AND SAFETY OF ACT-541468 IN ADULT AND ELDERLY SUBJECTS WITH INSOMNIA DISORDER

Intervention/treatment:
ACT-541468
Medical condition:
INSOMNIA
Protocol code:
ID-078A302
Control number:
216481
Status:
Closed
Approved:
June 20, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03575104
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Trial Disclosure Desk
Organization
Idorsia Pharmaceuticals Ltd
Phone:
+41 58 844 00 00
Sponsor
IDORSIA PHARMACEUTICALS LTD

Locations

CANADIAN PHASE ONWARD INC. (Toronto)
Toronto, M3J 0K2
Queensway Sleep Lab Sleep Clinic (MedSleep)- 5359 Dundas Street West, Suite 202, Etobicoke, ON M9B 1B1
Etobicoke, M9C 5N2
Somni Research, Calgary
Toronto, M3H 3W1
Somni Research Inc.
Markham, L3R 1A3

Ontario

Canadian Phase Onward Inc.
Toronto, Ontario, M3J 2C5
The Medical Arts Health Research Group
Kelowna, Ontario, V1Y 3G8

Results

See the results from the trial NCT03575104. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?